Physician profile
Hasib Sarij
NPI 1992888184
$7,596.02
in general payments reported to CMS, 2019-2025
54 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,025 · 2021: $1,225 · 2022: $695 · 2023: $814 · 2024: $1,629 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,210.32 | 2019-2024 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $944.10 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $659.89 | 2019-2025 | Ztlido |
| Tersera Therapeutics LLC | $577.22 | 2019-2025 | Prialt |
| Abbvie INC. | $409.49 | 2021-2025 | Qulipta, Botox |
| Allergan, INC. | $249.45 | 2019-2022 | |
| Indivior INC. | $233.49 | 2019-2023 | Sublocade |
| Medtronic, INC. | $203.97 | 2021-2024 | Synchromedii |
| Depuy Synthes Sales INC. | $202.75 | 2019-2025 | Orthovisc, Monovisc |
| Idorsia Pharmaceuticals US INC | $181.72 | 2022-2024 | Quviviq |
| Abbott Laboratories | $176.68 | 2019-2021 | |
| Boston Scientific Corporation | $175.31 | 2019-2021 | |
| Sentynl Therapeutics, INC. | $169.35 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $154.73 | 2020-2021 | |
| Bioventus LLC | $133.22 | 2019-2024 | Gelsyn-3 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $114.90 | 2020-2024 | Levorphanol Tartrate |
| Redhill Biopharma INC. | $102.24 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $101.91 | 2019-2021 | |
| Spinefrontier, INC. | $100.00 | 2024 | Inspan, Sijfuse |
| Valinor Pharma, LLC | $98.76 | 2023-2024 | Movantik |
| Nevro Corp. | $90.39 | 2021-2024 | Senza |
| Lilly USA, LLC | $81.32 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $79.84 | 2024-2025 | |
| Neuronetics, INC. | $79.09 | 2021-2024 | Neurostar Tms Therapy System |
| Flowonix Medical Incorporated | $65.22 | 2019 | |
| Djo, LLC | $58.80 | 2024 | Cmf |
| Supernus Pharmaceuticals, INC. | $58.65 | 2019-2022 | |
| Orexo US, INC. | $58.25 | 2019 | |
| Forte Bio-Pharma LLC | $53.69 | 2021-2023 | Prolate, Nalocet |
| Curonix LLC | $49.75 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Astrazeneca Pharmaceuticals Lp | $49.64 | 2019 | |
| Averitas Pharma INC. | $48.99 | 2025 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $48.52 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $47.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $46.68 | 2019 | |
| Novo Nordisk INC | $39.59 | 2023-2025 | Wegovy |
| Almatica Pharma LLC | $38.50 | 2021-2023 | Gralise |
| Protega Pharmaceutials INC | $35.77 | 2025 | Roxybond |
| Pfizer INC. | $34.92 | 2019-2021 | |
| Horizon Therapeutics Plc | $32.91 | 2019 | |
| Ibsa Pharma INC. | $32.72 | 2021 | |
| Shionogi INC | $29.48 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $28.78 | 2020-2021 | |
| Axsome Therapeutics, INC. | $24.93 | 2025 | Symbravo |
| Intra-Sana Laboratories | $24.89 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Mdd US Operations, LLC | $24.55 | 2019-2020 | |
| Grt US Holding, INC. | $21.55 | 2022 | |
| Amgen INC. | $18.73 | 2021 | |
| Vertical Pharmaceuticals, LLC | $18.35 | 2023 | Dsuvia |
| Baudax Bio INC. | $16.36 | 2020 | |
| Galderma Laboratories, L.P. | $15.90 | 2022 | |
| Assertio Therapeutics, INC. | $15.85 | 2019 | |
| Daiichi Sankyo INC. | $14.44 | 2019 | |
| Uswm, LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasib Sarij listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.